Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $1.9 million.

  • Tarsus Pharmaceuticals' Capital Expenditures rose 57730.5% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 13899.67%. This contributed to the annual value of $1.6 million for FY2024, which is 432.76% up from last year.
  • Tarsus Pharmaceuticals' Capital Expenditures amounted to $1.9 million in Q3 2025, which was up 57730.5% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Tarsus Pharmaceuticals' Capital Expenditures peaked at $1.9 million during Q3 2025, and registered a low of $16000.0 during Q2 2021.
  • In the last 5 years, Tarsus Pharmaceuticals' Capital Expenditures had a median value of $224500.0 in 2021 and averaged $425666.7.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Capital Expenditures crashed by 9522.39% in 2021, and later surged by 66250.0% in 2022.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Capital Expenditures stood at $274000.0 in 2021, then tumbled by 53.65% to $127000.0 in 2022, then skyrocketed by 195.28% to $375000.0 in 2023, then plummeted by 80.8% to $72000.0 in 2024, then surged by 2552.78% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.0 million for Q2 2025, and $590000.0 during Q1 2025.